Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen (AMGN – Research Report), Actinium Pharmaceuticals (ATNM – Research Report) and Axsome Therapeutics (AXSM – Research Report).
Actinium Pharmaceuticals (ATNM)
William Blair analyst Andy Hsieh reiterated a Buy rating on Actinium Pharmaceuticals on September 15. The company’s shares closed last Friday at $7.15.
According to TipRanks.com, Hsieh is a 4-star analyst with an average return of 15.6% and a 48.3% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Vaccitech Plc, and Beyondspring.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Actinium Pharmaceuticals with a $36.67 average price target, which is a 440.9% upside from current levels. In a report issued on September 15, JonesTrading also reiterated a Buy rating on the stock with a $40.00 price target.
Axsome Therapeutics (AXSM)
William Blair analyst Myles Minter reiterated a Buy rating on Axsome Therapeutics yesterday. The company’s shares closed last Friday at $28.88, close to its 52-week low of $19.38.
According to TipRanks.com, Minter is a 4-star analyst with an average return of 19.7% and a 51.3% success rate. Minter covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Ionis Pharmaceuticals, and Larimar Therapeutics.
Currently, the analyst consensus on Axsome Therapeutics is a Moderate Buy with an average price target of $93.75, a 228.2% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $180.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.